CD274 and neoplasm: Our study revealed that anti-PD-L1 scFv fused to the TCRγδ heterodimer could efficiently target PD-L1-expressing tumor cells with a similar potency to anti-PD-L1 CAR in both in vitro and in vivo solid tumor models (Figs. 2, 3).